Evaluation of targeted and immune combination therapies in a rat model of hormone receptor–positive breast cancer
Proceedings of the National Academy of Sciences · 2026
DOI: 10.1073/pnas.2501052123 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2026. Verfasst von Ernesto Rojas-Jimenez und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215. Hauptthemen laut MEDLINE: Receptors, Estrogen, Breast Neoplasms, Mammary Neoplasms, Experimental. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NIAID NIH HHS, Breast Cancer Research Foundation (BCRF).
Abstract (Originalsprache)
Estrogen receptor (ER) positive breast cancer is the most prevalent subtype, commonly responsive to endocrine therapies. Immune checkpoint inhibitors (ICIs) have limited efficacy in ER-positive disease, highlighting the need for the development of combination immunotherapies for these patients. We previously established that nitroso-N-methylurea-induced mammary tumors in outbred Sprague-Dawley rats mimic immune evasive mechanisms and the heterogeneity of ICI response observed in patients. We identified a “luminal growing” gene signature in ER-positive tumors, which correlated with tumor growth and immune-related differences. Here, we evaluated targeting candidates from this signature KMT5B/C and IKBKE using inhibitors A-196 and IKBKEi respectively, alongside anti-estrogen (fulvestrant) and a TGFβ blocking antibody (NIS793), both individually and in combination with αPD-L1, within this rat model. Fulvestrant emerged as the most effective treatment, inducing regression of most existing tumors and reducing on-treatment tumor burden when combined with αPD-L1. A-196, while ineffective as a monotherapy, demonstrated enhanced response when combined with αPD-L1. Comprehensive tumor profiling through polychromatic flow cytometry and single-cell RNA sequencing revealed that A-196 induced a luminal-to-basal shift in tumor epithelial cells, enhancing antigen presentation, whereas epithelial-to-mesenchymal transition was linked to fulvestrant resistance. Our findings underscore the value of the rat mammary tumor model for preclinical studies in ER-positive breast cancer and advocate for the further validation and potential clinical development of KMT5B/C inhibitors to enhance the efficacy and broaden the applicability of ICI therapy in cancer patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215.
- Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115.
- Department of Medicine, Harvard Medical School, Boston, MA 02115.
ORCID-Profile: Pengze Yan, Jun Nishida, Gordon J Freeman, Kornelia Polyak
Förderung
- NCI NIH HHS
- NIAID NIH HHS
- Breast Cancer Research Foundation (BCRF)
- Novartis AG | Novartis Institutes for BioMedical Research (NIBR)
- HHS | NIH | National Cancer Institute
- HHS | NIH
Zitieren
APA
Rojas-Jimenez, E., Bui, T. M., Yan, P., Li, Z., Seehawer, M., Nishida, J., Foidart, P., Freeman, G. J., & Polyak, K. (2026). Evaluation of targeted and immune combination therapies in a rat model of hormone receptor–positive breast cancer. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2501052123
Vancouver
Rojas-Jimenez E, Bui TM, Yan P, Li Z, Seehawer M, Nishida J, et al. Evaluation of targeted and immune combination therapies in a rat model of hormone receptor–positive breast cancer. Proceedings of the National Academy of Sciences. 2026. doi:10.1073/pnas.2501052123
BibTeX
@article{RojasJimenez2026,
author = {Rojas-Jimenez, Ernesto and Bui, Triet M and Yan, Pengze and Li, Zheqi and Seehawer, Marco and Nishida, Jun and Foidart, Pierre and Freeman, Gordon J and Polyak, Kornelia},
title = {Evaluation of targeted and immune combination therapies in a rat model of hormone receptor–positive breast cancer},
journal = {Proceedings of the National Academy of Sciences},
year = {2026},
doi = {10.1073/pnas.2501052123}
}
EUVIMED